JULIE AKINS: Open Payments
NPI 1285811505 · TWIN FALLS, ID. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,160 in 50 payments from 11 companies in 2025. Trend: 2023 $550 · 2024 $518 · 2025 $1,160
Food & beverage: $1,160
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 15 | $480 |
| ABBVIE INC. | 13 | $166 |
| Vanda Pharmaceuticals Inc. | 3 | $156 |
| Otsuka America Pharmaceutical, Inc. | 7 | $133 |
| Alkermes, Inc. | 5 | $101 |
| Lundbeck LLC | 1 | $26 |
| Teva Pharmaceuticals USA, Inc. | 1 | $24 |
| Corium, LLC | 2 | $22 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $19 |
| Neuronetics, Inc. | 1 | $17 |
Products named: CAPLYTA, FANAPT, VRAYLAR, ABILIFY ASIMTUFII, REXULTI, LYBALVI, ARISTADA, QULIPTA.
Industry payments across ID — which companies pay providers there.
